Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Brady NJ, Bagadion AM, Singh R, Conteduca V, Van Emmenis L, Arceci E, et al. Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer. Nat Commun. 2021;12(1):3372.

Soshnev AA, C Allis D, Cesarman E, Melnick AM. Histone H1 mutations in lymphoma: a link(er) between chromatin organization, developmental reprogramming, and cancer. Cancer Res. 2021.

Xu H, Magro C, Minkis K. Potential Masquerader of Malignancy: Tophaceous Gout Causing Nail Dystrophy. Dermatol Surg. 2021;47(8):1149-1150.

Haas T, Callum J, Grottke O, Asmis LM, Cushing MM. Response to Wirtz et al: The impact of blood product ratio and procoagulant therapy on the development of thromboembolic events in severely injured hemorrhaging trauma patients. Transfusion. 2021;61(3):991-992.

Matrai CE, Ohara K, Eng KW, Glynn SM, Chandra P, Chatterjee-Paer S, et al. Molecular Evaluation of Low-grade Low-stage Endometrial Cancer With and Without Recurrence. Int J Gynecol Pathol. 2021.

Nagirnaja L, Mørup N, Nielsen JE, Stakaitis R, Golubickaite I, Oud MS, et al. Variant , Defective piRNA Processing, and Azoospermia. N Engl J Med. 2021;385(8):707-719.

Sparano JA, Lee JY, Kaplan LD, Ramos JC, Ambinder RF, Wachsman W, et al. Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in HIV-associated, B-cell non-Hodgkin's lymphoma. Haematologica. 2021;106(3):730-735.

Khan U, Ho K, Hwang EK, Peña C, Brouwer J, Hoffman K, et al. Impact of Use of Antibiotics on Response to Immune Checkpoint Inhibitors and Tumor Microenvironment. Am J Clin Oncol. 2021;44(6):247-253.

Itkonen HM, Loda M, Mills IG. O-GlcNAc Transferase - An Auxiliary Factor or a Full-blown Oncogene? Mol Cancer Res. 2021;19(4):555-564.

Pham K, Gottesdiener L, Simon MS, Trzebucki A, Maldarelli GA, Cisse B, et al. Meningovascular Syphilis Presenting as a Brain Mass in an Immunocompetent Male. Open Forum Infect Dis. 2021;8(9):ofab455.